Search
Close this search box.
    • Small Molecules
      • Discovery
        Development
        Manufacturing
    • Biologics
      • Discovery
        Development & Manufacturing
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery

      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

        Know More
        Know More
    • Industries
    • Emerging Biopharma

      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

        Know More
        Know More
    • Dedicated Centers

      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

        Know More
        Know More
    • Center for Advanced Protein Studies (CAPS)

      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

        Know More
        Know More
    • Investors
      Corporate Governance
  • Careers
Search
Close this search box.

Stock Exchange Disclosures

Intimation of Annual Report FY23 under Regulation 34(1)
Open
Press Release- Syngene to Aquire Multi-Model facility from Stelis Biopharma Ltd
Open
Closure of Trading Window
Open
Communication to Shareholders on Final dividend
Open
Investor call with Mirae MF,Ashmore Investment Management and Mondrian Investment Partners
Open
Investor call with White Oak Capital and Aberdeen Asset Management
Open
Investor call with White Oak Capital and Aberdeen Asset Management
Open
Investor call with Polen Capital
Open
Investor call with Arohi Asset Management
Open
Investor call with Edelweiss AMC
Open
Investor call intimation -Skerryvore Asset Management and Bajaj Allianz Life Insurance
Open
Annual Disclosure by Large Corporate- May 11,2022
Open
Allottment of Trust - April 27, 2022
Open
Investor Meeting with APG Asset Management
Open
Revision in Rating ICRA
Open
Intimation regarding revision in rating under Regulation 30 of SEBI Listing Regulations.
Open
Change in Directorate
Open
Voting Result and Scruitinizer Report
Open
Investor meeting with CLSA
Open
Investor meeting with FSSA Investments and Edelweiss AMC
Open
Update on Interim disbursements from Insurer towards the loss from fire incident reported in December 2016
Open
Investor Call with FSSA Investment Managers
Open
Investor Call with Bay Capital
Open
Intimation of Schedule of Meetings with Institutional Investors
Open
Advertisement in Newspapers – Financial Results Q3 FY21
Open
Outcome of Board Meeting - Q3FY21
Open
Intimation of Q3FY21 Investor Presentation
Open
Q3FY21 Press Release-Intimation
Open
Conference call for Analysts and Investors to be held on January 21,2021
Open
Advertisement in Newspapers – Notice of Board Meeting to be held on January 20, 2021
Open
Q4FY19 Board Meeting Intimation
Open
Q4FY19 Press Release March 2019-Intimation
Open
The Outcome of Board Meeting- Q4FY19
Open
Investor Presentation March 2019- Intimation
Open
Resignation of CS -Intimation
Open
Investor Meetings with Pari Washington Company Advisors, Jefferies ASEAN and India Corporate Access Days, Axis Capital 12th Annual Conference, B and K Annual Conference
Open
Investor Meeting with Canara Robeco Asset Management Company Ltd.
Open
Investor Meeting with Seven Canyons Advisors
Open
Postal Ballot Notice Intimation May 2019
Open
Investor Meeting with Mondrian Investment Partners.
Open
Sale of Share by Promoter to Achieve Minimum Public Shareholding
Open
Completion of Sale of Shares by Promoter
Open
Syngene Announces Partnership with Zumutor Biologics for Biotherapeutic Antibody Discovery Services- Press Release
Open
Intimation of AGM 2018
Open
Intimation of AGM 2018: Newspaper Ad
Open
Q1FY19 Board Meeting Intimation
Open
The outcome of BM -Audited Financial Results Q1FY19
Open
Investor Presentation June 2018- Intimation
Open
Q1FY19 Press Release June2018-Intimation
Open
Voting Results AGM July 2018
Open
Investors Meetings- Dated till May 29th
Intimation of AGM 2017
Intimation of AGM 2017: Newspaper Ad
Board Meeting Intimation July27 2017
Open
Board Meeting Intimation: Newspaper Ad
Intimation-Outcome of BM -Audited Financial Results
Open
Syngene -Voting results under Regulation 44(3) of SEBI
Open
Syngene 24th AGM Proceeding July 2017
Open
Intimation-Outcome of BM -Audited Financial Results
Open
New Appointment in Board
Open
Board Meeting Intimation: 21st,July-2016
Open
Financial Results Q1 FY17
Open
Investors Meeting with Ambit Capital, SBI Life Insurance Co Ltd, Motilal Oswal 12th Annual Global Investor Confrence 2016, Motilal Oswal Roadshow in Asia , Axis Capital 10th Annual Conference
Open
Syngene-SARC PressRelease,2016
Open
Syngene strand PressRelease,2016
Open
Investors Meeting with Dalal & Broacha Stock Broking Private Limited,Haitong Securities India Private Limited & Geneva Advisors, LLC
Open
Board Meeting Intimation: 20th,October-2016
Open
Board Meeting Intimation: Newspaper Ad
Open
Investor Presentation-Oct2016
Open
Investors Meeting with Mondrian Investment Partners, Mawer Investments, I Wealth Management, Templeton Asset Management Limited, Matthews India Fund, Marathon Asset Management, Matthews Asia
Open
Syngene Postal Ballot Results - 2015
Open
Intimation of Scheduled Meetings
Open
Change in KMP
Open
Interim Dividend Intimation to Stock Exchange
Open
Syngene Dividend Declaration- March 2016
Open
Investors Presentation at Jefferies India Corporate Day- March 2016
Open
Investors Meeting with Karst Peak Capital, Batlivala &Karani, Cartica Capital
Open
Investors Meeting with BlackRock UK, Nomura Securities, Ward Ferry Management Ltd
Open
Investors Meeting with Nomura Securities is cancelled
Open
Intimation of Board Meeting
Open

Email subscription services

Have more questions?

Contact Investor Relations
Contact Investor Relations

© 2023. Syngene International Limited

Twitter Linkedin-in Youtube Facebook-f

Quick Links

Business

Get In Touch

Other Links

Twitter Linkedin-in Youtube Facebook-f

© 2023. Syngene International Limited

Download PDF
Download PDF

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy. and
Close

To view or email, Please share your details view

To download, Please share your details